ATE283925T1 - Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann - Google Patents

Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Info

Publication number
ATE283925T1
ATE283925T1 AT97930902T AT97930902T ATE283925T1 AT E283925 T1 ATE283925 T1 AT E283925T1 AT 97930902 T AT97930902 T AT 97930902T AT 97930902 T AT97930902 T AT 97930902T AT E283925 T1 ATE283925 T1 AT E283925T1
Authority
AT
Austria
Prior art keywords
inducing
block
human
cell tolerance
binding
Prior art date
Application number
AT97930902T
Other languages
English (en)
Inventor
Boer Mark De
Original Assignee
Tanox Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Pharma B V filed Critical Tanox Pharma B V
Application granted granted Critical
Publication of ATE283925T1 publication Critical patent/ATE283925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
AT97930902T 1996-07-23 1997-07-23 Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann ATE283925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2207096P 1996-07-23 1996-07-23
PCT/NL1997/000438 WO1998003670A1 (en) 1996-07-23 1997-07-23 Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Publications (1)

Publication Number Publication Date
ATE283925T1 true ATE283925T1 (de) 2004-12-15

Family

ID=21807674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930902T ATE283925T1 (de) 1996-07-23 1997-07-23 Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Country Status (8)

Country Link
US (1) US20020150559A1 (de)
EP (1) EP0922111B1 (de)
JP (1) JP4219985B2 (de)
AT (1) ATE283925T1 (de)
CA (1) CA2260752A1 (de)
DE (1) DE69731836T2 (de)
HK (1) HK1017905A1 (de)
WO (1) WO1998003670A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988321A2 (de) * 1997-06-20 2000-03-29 Innogenetics N.V. B7-bindungsmolekülen zur behandlung von immunkrankheiten
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
FR2789089A1 (fr) * 1999-02-02 2000-08-04 Pf Medicament Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
EP1839674A1 (de) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40-Antagonist zur Behandlung von Psoriase
CA2406961A1 (en) * 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059888A1 (en) * 2001-08-22 2003-03-27 Shengfeng Li Compositions and methods for generating antigen-binding units
CA2516832A1 (en) * 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
EP1658096A1 (de) * 2003-08-25 2006-05-24 PanGenetics B.V. Verfahren zur auslösung von immuntoleranz
EP1854810A1 (de) 2006-05-09 2007-11-14 PanGenetics B.V. De-immunisierter und antagonister monoclonaler Antikörper gegen CD40, der aus der ch5D12 Antikörper abgeleitet ist
ES2622460T3 (es) * 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
MX338825B (es) * 2008-10-02 2016-05-03 Emergent Product Dev Seattle Proteinas de enlace a objetivos multiples de antagonistas de cd86.
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
EP2948475A2 (de) * 2013-01-23 2015-12-02 AbbVie Inc. Verfahren und zusammensetzungen zur modulierung einer immunantwort
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
EP2930188A1 (de) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunktionelles Antigen-bindendes Molekül
KR20220025917A (ko) 2014-05-29 2022-03-03 마크로제닉스, 인크. 삼중-특이적 결합 분자 및 그것의 사용 방법
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
AU2016334041B2 (en) 2015-10-08 2023-02-09 Macrogenics, Inc. Combination therapy for the treatment of cancer
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
EP0922111B1 (de) 2004-12-01
HK1017905A1 (en) 1999-12-03
DE69731836D1 (de) 2005-01-05
JP4219985B2 (ja) 2009-02-04
CA2260752A1 (en) 1998-01-29
JP2000515374A (ja) 2000-11-21
WO1998003670A1 (en) 1998-01-29
EP0922111A1 (de) 1999-06-16
DE69731836T2 (de) 2005-12-01
US20020150559A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE283925T1 (de) Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
TR199902124T2 (xx) �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller.
CA2281684A1 (en) Inhibition of cell-cell binding by lipid assemblies
DE69406423T2 (de) Methode zum überbringen von agenzien an zielzellen
DE69713628T2 (de) Verfahren zum herstellen von blattförmigen artikeln, insbesondere schleifartikel
DE69433552D1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
AU6632496A (en) Cell derived antigen presenting vesicles
EP1746160A3 (de) Hepatozyt-Wachstumsfaktor-Rezeptor-Antagonisten und deren Anwendung
DE60336059D1 (de) Verfahren zu deren verwendung
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
ATE353906T1 (de) Cd27 ligand
BR0210699A (pt) Métodos para aperfeiçoamento da função de células retinais danificadas
EP0739350A4 (de) Fas-antigenbindender ligand
NL300307I1 (nl) Werkwijzen voor de replicatie van influenzavirussen in celkweek en de influenzavirussen die verkrijgbaar zijn met behulp van de werkwijze
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
GB9905911D0 (en) Method
ATE243319T1 (de) Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden
EP0754229A1 (de) Afamin: ein menschliches serum albumin ähnliches protein
WO2003038062A3 (en) Generation of use of tc1 and tc2 cells
PT805169E (pt) Processo para o fabrico de copolimeros soluveis em meio alcalino a base de (met)acrilatos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties